{ 124件 }
Kitsunai H, Shinozaki Y, Furusawa S, Kitao N, Ito M, Kurihara H, Oba-Yamamoto C, Takeuchi J, Nakamura A, Takiyama Y, Nomoto H.
The Effect of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: Post-Hoc Analysis of the Sapporo-Oral SEMA Study Pharmaceuticals, in press
IF: 4.3
Yuka Suzuki MD, Aika Miya MD, PhD, Akinobu Nakamura MD, PhD, Takahisa Handa MD, PhD, Hiraku Kameda MD, PhD, Tatsuya Atsumi MD, PhD Perception of hyper-/hypoglycemia and its related factors in type 2
diabetes: A continuous glucose monitoring based prospective observational study Diabetology International, in press IF 1.3
Takahashi A, Nomoto H*, Yokoyama H, Yokozeki K, Furusawa S, Oe Y, Kameda R, Kawata S, Miyoshi A, Nagai S, Miya A, Kameda H, Nakamura A, Atsumi T.
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Diabetes Obes Metab, in press
IF 5.4
Oe Y, Nomoto H, Cho KY, Yokozeki K, Ono T, Miya A, Kameda H, Nakamura A, Arimura Y, Atsumi T. Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study).
BMC Endocr Disord. in press
IF: 2.8
Maiko Miyamoto, Akinobu Nakamura, Aika Miya, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Naoya Iwahara, Kiyohiko Hotta, Nobuo Shinohara, Tatsuya Atsumi.
Normalization of impaired glucose tolerance after kidney transplantation is associated with improved beta-cell function.
Am J Physiol Endocrinol Metab, in press.
IF 5.1
日本臨床分子医学会 学会賞 中村昭伸先生
Takahashi A, Nomoto H, Onishi K, Manda S, Miya A, Kameda H, Nakamura A, Atsumi T.
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study)
Diabete Obes Metab. in press
IF 5.8
Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Kurihara Y, Nakamura A, Atsumi T.
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post-Hoc Analysis.
J Clin Endocr Metab, in press.
IF: 5.8
Asia Islet Biology and Incretin Research Association (AIBIS) 2024
トラベルグラント 千葉 幸輝先生
Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, and Tatsuya Atsumi Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study) ENDOCRINE JOURNAL, in press
IF: 2.0